Dear Reader

As we reach the final issue of the year for *Drugs in R&D*, we hope that you have found the articles published throughout 2010 to be both interesting and informative. This year saw *Drugs in R&D* being transformed from subscription based to open access, making it the first Adis journal to embrace the open-access model. The editors and publishing staff have appreciated the high quality of content contributed to the journal this year and were pleased to see a 35% increase in the *Drugs in R&D* ISI impact factor (IF) to 1.354.

The high quality of other Adis Journals was also recognized in the new ISI IFs for 2009 with ten of our titles making strong IF gains over 2008. The most impressive gains were made by *BioDrugs* (IF 3.506; up \<55%), *Drugs* (IF 4.732; up \<14%), and the *American Journal of Clinical Dermatology* (IF 1.820; up \<17%). The *American Journal of Cardiovascular Drugs*, a newly tracked journal in 2009, received its first IF (1.964) and was ranked \#47 in the 'Cardiac & Cardiovascular System' category. *Pediatric Drugs* was accepted for inclusion in Current Contents/Clinical Medicine and a Thompson ISI IF for the journal is expected in 2013. This year, we also celebrated the 10th anniversary of the *American Journal of Clinical Dermatology* making significant contributions to the field of dermatology.

We would like to say a big thank you to all the authors who have contributed articles to *Drugs in R&D* in the last 12 months. Without their hard work and diligence we would not have been able to publish the journal. The quality of published articles also reflects the significant time and effort dedicated by the peer reviewers, who ensure that we continue to publish content of the highest possible standard. In addition to the members of our Honorary Editorial Board, we would like to thank the following individuals who acted as referees for articles published in *Drugs in R&D* in 2010:

*Omar Ali*, USA

*Ken Arai*, USA

*Daniela Bruttomesso*, Italy

*S. Cai*, USA

*Si Duanyun*, China

*Nathalie P. Duroudier*, UK

*Run-lin Gao*, China

*Robert Hermann*, Germany

*Aidan A. Hollis*, Canada

*Li Hua*, China

*N. Hunfeld*, the Netherlands

*W.H. Jost*, Germany

*S. Karoui*, Tunisia

*Charanjit Kaur*, India

*Jennifer Keiser*, Switzerland

*Miles A. Kirchin*, Germany

*Ran Kornowski*, Israel

*Anthony L. Kovac*, USA

*E. Kul-Panza*, Turkey

*Shiu K. Lam*, China

*Alain Lachaux*, France

*Paul A. Lapchak*, USA

*Frank R. Lichtenberg*, USA

*Robert T. Malison*, USA

*Hiroto Matsuse*, Japan

*James M. McKenney*, USA

*Sebastian Muller*, France

*Ryuichi Ogawa*, Japan

*Yoshiyuki Ohno*, Japan

*Hitoshi Osaka*, Japan

*Brita A. Pekarsky*, Australia

*Yihong Qiu*, USA

*Ian Sayers*, UK

*Dorothea Sesardic*, UK

*Dirk D. Skowasch*, Germany

*Takenori Takahata*, Japan

*Zhiqun Tan*, USA

*Anna Tavridou*, Greece

*Henrik S. Thomsen*, Denmark

*Yoshito Tsushima*, Japan

*Paul M. Tulkens*, Belgium

*Yoshiko Unno*, Japan

*T. Velpandian*, India

*Liang Xu*, USA

*T. Yasuda*, Japan

We look forward to your continued support and keeping you up-to-date with topical issues in the field of drug research in 2011. With best wishes from the staff of *Drugs in R&D* and all at Adis, a Wolters Kluwer business.
